secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2021-08-04T23:59:59+00:00
Accession:  0001104659-21-100117
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharmaceuticals appoints Brian Varnum as CEO; Todd Patrick resigns but stays as advisor
--------------------------------------------------------------------------------

- Brian Varnum, Ph.D. appointed CEO effective August 1, 2021; was previously President and Chief Development Officer.
- Todd R. Patrick resigned as CEO as of Aug 1, 2021; continues as board member until next annual meeting and as advisor through Dec 31, 2022.
- Patrick to receive base salary of $550K through Dec 2021, then $275K through transition period; target bonus 50% of base.
- Varnum receives base salary $500K, target bonus 50%, and option to purchase 125,000 shares vesting over 4 years.
- Half of Patrick's unvested stock options and RSUs vest at end of transition period if he serves full term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465921100117/0001104659-21-100117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465921100117/tm2124032d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-100117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer